Sanofi Australia has received
TGA approval for its Zaltrap
(aflibercept rch) in combination
with irinotecan-fluoropyrimidinebased
chemotherapy for use in
adults with metastatic colorectal
cancer previously treated with an
oxaliplatin-containing regimen.
In Australia, colorectal cancer is
the second most common cancer in
both men and women.
Zaltrap is a recombinant fusion
protein which acts as a decoy
receptor binding to growth factors
related to angiogenesis.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Apr 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.